Inventor · disambiguated record
Birgit Schoeberl
Also filed as: SCHOEBERL BIRGIT · SCHOEBERL BIRGIT M
16 granted patents·18 pending applications·285 citations·filing 2005–2024
95Inventor score
Files withMERRIMACK PHARMACEUTICALS INC16SILVER CREEK PHARMACEUTICALS INC7SCHOEBERL BIRGIT4ELEVATION ONCOLOGY INC2NIELSEN ULRIK2
Top patents by PatentIndex Score
34 records- 0198US7846440B2Antibodies against ErbB3 and uses thereofMERRIMACK PHARMACEUTICALS INC·Filed 2008·Granted Dec 7, 2010·92 cites·18 claims
- 0295US9238080B2Bi-specific fusion proteinsNIELSEN ULRIK·Filed 2011·Granted Jan 19, 2016·29 cites·21 claims
- 0394US10988547B2Bi-specific fusion proteinsSILVER CREEK PHARMACEUTICALS INC·Filed 2019·Granted Apr 27, 2021·6 cites·7 claims
- 0494US9718892B2Method of treating myocardial infarction by administering a bi-specific fusion proteinMERRIMACK PHARMACEUTICALS INC·Filed 2015·Granted Aug 1, 2017·12 cites·10 claims
- 0594US8961966B2Antibodies against ERBB3 and uses thereofSCHOEBERL BIRGIT·Filed 2010·Granted Feb 24, 2015·20 cites·15 claims
- 0694US8691771B2Bi-specific fusion proteins for tissue repairNIELSEN ULRIK·Filed 2011·Granted Apr 8, 2014·21 cites·9 claims
- 0794US8691225B2Antibodies against the ectodomain of ErbB3 and uses thereofSCHOEBERL BIRGIT·Filed 2009·Granted Apr 8, 2014·26 cites·20 claims
- 0894US8124085B2Bispecific binding agents for modulating biological activityNIELSEN ULRIK B·Filed 2005·Granted Feb 28, 2012·29 cites·9 claims
- 0993US10858450B2Bi-specific fusion proteinsSILVER CREEK PHARMACEUTICALS INC·Filed 2018·Granted Dec 8, 2020·6 cites·7 claims
- 1093US10407512B2Bi-specific fusion proteinsSILVER CREEK PHARMACEUTICALS INC·Filed 2017·Granted Sep 10, 2019·9 cites·8 claims
- 1191US9982060B2Bi-specific fusion proteinsMERRIMACK PHARMACEUTICALS INC·Filed 2014·Granted May 29, 2018·9 cites·15 claims
- 1291US8440192B2Bispecific binding agents for modulating biological activityNIELSEN ULRIK B·Filed 2012·Granted May 14, 2013·11 cites·21 claims
- 1390US11814443B2Bi-specific fusion proteinsSILVER CREEK PHARMACEUTICALS INC·Filed 2021·Granted Nov 14, 2023·1 cites·20 claims
- 1490US2024360243A1Antibodies against the ectodomain of erbb3 and uses thereofELEVATION ONCOLOGY INC·Filed 2024·Application pending·0 cites
- 1589US2024101713A1Bi-Specific Fusion ProteinsSILVER CREEK PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1688US11673970B2Bi-specific fusion proteinsSILVER CREEK PHARMACEUTICALS INC·Filed 2020·Granted Jun 13, 2023·1 cites·7 claims
- 1787US8623592B2Methods and systems for predicting response of cells to a therapeutic agentSCHOEBERL BIRGIT·Filed 2009·Granted Jan 7, 2014·9 cites·11 claims
- 1887US2023322951A1Bi-Specific Fusion ProteinsSILVER CREEK PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1985US9487588B2Antibodies against the ectodomain of ERBB3 and uses thereofMERRIMACK PHARMACEUTICALS INC·Filed 2014·Granted Nov 8, 2016·4 cites·4 claims
- 2079US2022204642A1Antibodies against the ectodomain of erbb3 and uses thereofELEVATION ONCOLOGY INC·Filed 2021·Application pending·0 cites
- 2169US2010056761A1Antibodies against erbb3 and uses thereofMERRIMACK PHARMACEUTICALS INC·Filed 2009·Application pending·0 cites
- 2269US2019292271A1Antibodies against the ectodomain of erbb3 and uses thereofMERRIMACK PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 2367US2014127238A1Methods, systems and products for predicting response of tumor cells to a therapeutic agent and treating a patient according to the predicted responseMERRIMACK PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 2463US2017073427A1Antibodies against the ectodomain of erbb3 and uses thereofMERRIMACK PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 2558US2017307631A1Methods, systems and products for predicting response of tumor cells to a therapeutic agent and treating a patient according to the predicted responseMERRIMACK PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 2657US2011027291A1Methods, systems and products for predicting response of tumor cells to a therapeutic agent and treating a patient according to the predicted responseMERRIMACK PHARMACEUTICALS INC·Filed 2010·Application pending·0 cites
- 2755US2013183311A1Bispecific binding agents for modulating biological activityMERRIMACK PHARMACEUTICALS INC·Filed 2013·Application pending·0 cites
- 2854US2017210809A1Bispecific binding agents targeting the igf-1r and erbb3 pathways and uses thereofMERRIMACK PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 2950US2012244163A1Bispecific binding agents targeting igf-1r and erbb3 signalling and uses thereofSCHOEBERL BIRGIT·Filed 2012·Application pending·0 cites
- 3045US2017327556A1Cartilage-binding fusion proteinsMERRIMACK PHARMACEUTICALS INC·Filed 2017·Application pending·0 cites
- 3143US2009246206A1Bispecific binding agents for modulating biological activityMERRIMACK PHARMACEUTICALS INC·Filed 2005·Application pending·0 cites
- 3238US2018244785A1Anti-fgfr antibodies and methods of useMERRIMACK PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 3338US2015231238A1Overcoming resistance to erbb pathway inhibitorsGARCIA GABRIELA·Filed 2012·Application pending·0 cites
- 3436US2019077870A1Engineered trail for cancer therapyMERRIMACK PHARMACEUTICALS INC·Filed 2017·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Birgit Schoeberl files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →